{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:03:41Z","timestamp":1787504621319,"version":"build-2736575974"},"reference-count":269,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2021.113155","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T09:43:40Z","timestamp":1610358220000},"page":"113155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0272-5465","authenticated-orcid":false,"given":"Harsh S.","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-8417","authenticated-orcid":false,"given":"Palak K.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath D.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113155_bib1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2174\/1381612821666150105143358","article-title":"Impact of early life stress on the pathogenesis of mental disorders: relation to brain oxidative stress","volume":"21","author":"Schiavone","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113155_bib2","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1038\/nature16028","article-title":"Brain and other nervous system disorders across the lifespan-global challenges and opportunities","volume":"527","author":"Silberberg","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113155_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brainresbull.2019.02.005","article-title":"Cumulative multiple early life hits- a potent threat leading to neurological disorders","volume":"147","author":"Sarkar","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib4","first-page":"527","article-title":"Treating neuropsychiatric disorders with PDE10A inhibitors, Drug Discov","volume":"3","author":"Siuciak","year":"2006","journal-title":"Today Ther. Strateg."},{"key":"10.1016\/j.ejmech.2021.113155_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib6","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib7","article-title":"Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder, Transl","volume":"6","author":"Macmullen","year":"2016","journal-title":"Psychiatry"},{"key":"10.1016\/j.ejmech.2021.113155_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1369\/jhc.2009.953471","article-title":"Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species","volume":"57","author":"Stephenson","year":"2009","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.ejmech.2021.113155_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3\u2019, 5\u2019-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2021.113155_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2021.113155_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2021.113155_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113155_bib13","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1074\/jbc.M511468200","article-title":"cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11","volume":"281","author":"Gross-Langenhoff","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/mol.65.2.267","article-title":"Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins","volume":"65","author":"Zoraghi","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113155_bib15","doi-asserted-by":"crossref","first-page":"19657","DOI":"10.1074\/jbc.M800595200","article-title":"Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP","volume":"283","author":"Handa","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib16","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1073\/pnas.0700279104","article-title":"Structural insight into substrate specificity of phosphodiesterase 10","volume":"104","author":"Wang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113155_bib17","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.113155_bib18","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1021\/jm040217u","article-title":"The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases","volume":"48","author":"Manallack","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib19","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm900521k","article-title":"Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research - still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib21","series-title":"Adv. Neurobiol.","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-3-319-58811-7_14","article-title":"PDE inhibitors for the treatment of schizophrenia","author":"Snyder","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113155_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2021.113155_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2021.113155_bib24","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113155_bib25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum- and testis-specific phosphodiesterase PDE10A: isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2021.113155_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jnnp.72.1.12","article-title":"Neuropsychiatry of the basal ganglia","volume":"72","author":"Ring","year":"2002","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2021.113155_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1192\/apt.6.2.83","article-title":"Adolescent schizophrenia","volume":"6","author":"Hollis","year":"2000","journal-title":"Adv. Psychiatr. Treat."},{"key":"10.1016\/j.ejmech.2021.113155_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"van Os","year":"2009","journal-title":"Schizophrenia, Lancet"},{"key":"10.1016\/j.ejmech.2021.113155_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020141","article-title":"A\u00a0systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molbrainres.2004.09.029","article-title":"The molecular genetics of the 22q11-associated schizophrenia","author":"Karayiorgou","year":"2004","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113155_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4236\/ojpsych.2013.31008","article-title":"Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs","volume":"3","author":"Cacabelos","year":"2013","journal-title":"Open J. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113155_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.ejmech.2021.113155_bib34","series-title":"Ann. N. Y. Acad. Sci., United States","first-page":"138","article-title":"Glutamate, dopamine, and schizophrenia from pathophysiology to treatment","author":"Laruelle","year":"2003"},{"key":"10.1016\/j.ejmech.2021.113155_bib35","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1055\/s-0030-1248317","article-title":"Computational modeling of synaptic neurotransmission as a tool for assessing dopamine hypotheses of schizophrenia","volume":"43","author":"Qi","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejmech.2021.113155_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-25758-2_10","article-title":"Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications","volume":"213","author":"Coyle","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113155_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fpsyt.2014.00030","article-title":"Computational neuropsychiatry - schizophrenia as a cognitive brain network disorder","volume":"5","author":"Dauvermann","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113155_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fncom.2015.00031","article-title":"Improper activation of D1 and D2 receptors leads to excess noise in prefrontal cortex","volume":"9","author":"Avery","year":"2015","journal-title":"Front. Comput. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III - the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/schbul\/sbn176","article-title":"Dysconnection in Schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring","volume":"35","author":"Stephan","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.biopsych.2005.10.005","article-title":"Synaptic plasticity and dysconnection in schizophrenia","volume":"59","author":"Stephan","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113155_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2021.113155_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113155_bib44","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","article-title":"Phosphodiesterase 10 inhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery","volume":"25","author":"Zagorska","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1389450053344975","article-title":"Huntingtons disease: new frontiers for molecular and cell therapy","volume":"6","author":"Melone","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2021.113155_bib46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2021.113155_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113155_bib48","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2021.113155_bib49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12974-019-1649-3","article-title":"The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson\u2019s disease mouse models","volume":"16","author":"Lee","year":"2019","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2021.113155_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03159935","article-title":"Pathology of Parkinson\u2019s disease - changes other than the nigrostriatal pathway","volume":"14","author":"Jellinger","year":"1991","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.ejmech.2021.113155_bib51","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113155_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/13543776.2020.1709444","article-title":"Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present)","volume":"30","author":"Zag\u00f3rska","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113155_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2011.04.006","article-title":"PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology","volume":"43","author":"Giorgi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2021.113155_bib54","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/brain\/awv219","article-title":"Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson\u2019s disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2021.113155_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw030","article-title":"Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications","volume":"19","author":"Heckman","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2021.113155_bib56","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1073\/pnas.93.24.13445","article-title":"Toward a molecular definition of long-term memory storage","volume":"93","author":"Bailey","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113155_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0165-0270(89)90016-2","article-title":"Long-term potentiation: studies in the hippocampal slice","volume":"28","author":"Sarvey","year":"1989","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.ejmech.2021.113155_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/jpet.116.237388","article-title":"TAK-063, a novel phosphodiesterase 10A inhibitor, protects from striatal neurodegeneration and ameliorates behavioral deficits in the R6\/2 mouse model of Huntington\u2019s diseases","volume":"360","author":"Harada","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113155_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.115.230482","article-title":"The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models","volume":"356","author":"Shiraishi","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113155_bib60","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hipo.22128","article-title":"PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington\u2019s disease mouse model","volume":"23","author":"Giralt","year":"2013","journal-title":"Hippocampus"},{"key":"10.1016\/j.ejmech.2021.113155_bib61","first-page":"16","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801, Behav","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib62","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib63","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1074\/jbc.M110.204453","article-title":"Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease","volume":"286","author":"Shi","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib64","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1111\/j.1471-4159.2007.04942.x","article-title":"Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain","volume":"103","author":"Liang","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113155_bib65","doi-asserted-by":"crossref","first-page":"69264","DOI":"10.18632\/oncotarget.20566","article-title":"Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking \u03b2-catenin and MAPK signaling","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113155_bib66","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/onc.2014.94","article-title":"A\u00a0novel target for selective inhibition of colon tumor cell growth and \u03b2-catenin-dependent TCF transcriptional activity","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113155_bib67","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/\u03b2-catenin-mediated transcription in human breast tumor cells","volume":"4","author":"Tinsley","year":"2011","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib68","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.18632\/oncotarget.6705","article-title":"\u03b2-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113155_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lfs.2019.05.043","article-title":"Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors","volume":"230","author":"Mehta","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2021.113155_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0018136","article-title":"Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling","volume":"6","author":"Tian","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113155_bib71","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/acs.jmedchem.9b00224","article-title":"Validation of phosphodiesterase-10 as a novel target for pulmonary arterial hypertension via highly selective and subnanomolar inhibitors","volume":"62","author":"Huang","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib72","article-title":"Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2021.113155_bib73","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.bmcl.2007.02.061","article-title":"PDE-10A inhibitors as insulin secretagogues","volume":"17","author":"Cantin","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib74","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.bmcl.2016.07.054","article-title":"Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors","volume":"26","author":"Meegalla","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib75","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/0023210-200822120-00002","article-title":"The role of phosphodiesterases in schizophrenia: therapeutic implications","volume":"22","author":"Siuciak","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2021.113155_bib76","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib77","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17460441.2.7.1001","article-title":"Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia","volume":"2","author":"Siuciak","year":"2007","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113155_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.joms.2010.06.178","article-title":"Schizophrenia: current therapy and review","volume":"69","author":"Weiss","year":"2011","journal-title":"J.\u00a0Oral Maxillofac. Surg."},{"key":"10.1016\/j.ejmech.2021.113155_bib79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mehy.2013.03.013","article-title":"A\u00a0serotonin hypothesis of schizophrenia","volume":"80","author":"Eggers","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejmech.2021.113155_bib80","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2021.113155_bib81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.baga.2013.08.001","article-title":"Modulation of striatal neuron activity by cyclic nucleotide signalling and phosphodiesterase inhibition","volume":"3","author":"Threlfell","year":"2013","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.ejmech.2021.113155_bib82","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: a critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib83","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00213-013-3371-7","article-title":"Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating","volume":"231","author":"Gresack","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2021.113155_bib84","series-title":"Conn\u2019s Transl. Neurosci","first-page":"219","article-title":"The basal ganglia","author":"Noorani","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113155_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.113155_bib87","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2021.113155_bib89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/ijms18040696","article-title":"Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair","volume":"18","author":"Knott","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113155_bib90","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejcb.2006.02.004","article-title":"Structure and dynamics of PKA signaling proteins","volume":"85","author":"Kim","year":"2006","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neures.2009.05.005","article-title":"Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain","volume":"65","author":"Rajput","year":"2009","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib92","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nn.2153","article-title":"Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs","volume":"11","author":"Bateup","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib93","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/45251","article-title":"Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons","volume":"402","author":"Bibb","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113155_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0896-6273(95)90294-5","article-title":"Modulation of calcium currents by a D1 dopaminergic protein kinase\/phosphatase cascade in rat neostriatal neurons","volume":"14","author":"Surmeier","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2021.113155_bib95","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1046\/j.1460-9568.1998.00142.x","article-title":"Modulation of the voltage-gated sodium current in rat striatal neurons by DARPP-32, an inhibitor of protein phosphatase","volume":"10","author":"Schiffmann","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib96","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0896-6273(00)80144-0","article-title":"Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit","volume":"16","author":"Roche","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2021.113155_bib97","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.113.211904","article-title":"Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs","volume":"349","author":"Megens","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113155_bib98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.10R01FM","article-title":"Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission","volume":"114","author":"Nishi","year":"2010","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2021.113155_bib99","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1021\/jm3004976","article-title":"Current landscape of phosphodiesterase 10A (PDE10A) inhibition","volume":"55","author":"Chappie","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543776.2012.739157","article-title":"Phosphodiesterase 10A inhibitors: a 2009 \u2013 2012 patent update","volume":"23","author":"Kehler","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113155_bib101","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543770903431050","article-title":"Patented PDE10A inhibitors: novel compounds since 2007","volume":"19","author":"Kehler","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113155_bib102","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2174\/1389450120666190801114210","article-title":"Advances in the discovery of PDE10A inhibitors for CNS-related disorders. Part 2: focus on schizophrenia","volume":"20","author":"\u015awierczek","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2021.113155_bib103","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1021\/jm1002793","article-title":"Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors","volume":"53","author":"H\u00f6fgen","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib104","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1021\/jm2009138","article-title":"Highly potent, selective, and orally active phosphodiesterase 10A inhibitors","volume":"54","author":"Malamas","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1021\/jm060653b","article-title":"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors","volume":"50","author":"Chappie","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib106","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1021\/jm2001508","article-title":"Use of structure-based design to discover a potent, selective, in\u00a0vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia","volume":"54","author":"Helal","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib107","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.bmcl.2012.07.076","article-title":"Novel triazines as potent and selective phosphodiesterase 10A inhibitors","volume":"22","author":"Malamas","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib108","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1016\/j.bmcl.2011.05.100","article-title":"N-Acylhydrazones as inhibitors of PDE10A","volume":"21","author":"Gage","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib109","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1016\/j.bmcl.2012.07.007","article-title":"Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia","volume":"22","author":"Cutshall","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib110","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1016\/j.bmcl.2011.04.067","article-title":"Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors","volume":"21","author":"Kehler","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib111","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.bmc.2010.10.038","article-title":"Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors","volume":"19","author":"Asproni","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib112","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejmech.2014.07.020","article-title":"Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors","volume":"84","author":"Dore","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib113","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1016\/j.bmc.2013.07.030","article-title":"N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors","volume":"21","author":"Kilburn","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib114","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1016\/j.bmc.2015.06.019","article-title":"BN\/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors","volume":"23","author":"Vlasceanu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib115","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.bmcl.2012.01.086","article-title":"Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors","volume":"22","author":"Hu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib116","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1016\/j.bmcl.2012.09.010","article-title":"Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)","volume":"22","author":"Hu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib117","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1016\/j.bmcl.2012.10.078","article-title":"Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux","volume":"22","author":"Rzasa","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib118","doi-asserted-by":"crossref","first-page":"8781","DOI":"10.1021\/jm401234w","article-title":"Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)","volume":"56","author":"Hu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib119","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1021\/jm500713j","article-title":"Discovery of clinical candidate 1-(4-(3-(4-(1 H-benzo[ d ]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), A potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A)","volume":"57","author":"Hu","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib120","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1016\/j.bmc.2014.10.013","article-title":"Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility","volume":"22","author":"Rzasa","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib121","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1248\/cpb.c14-00509","article-title":"Synthesis and in\u00a0vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors","volume":"62","author":"Hamaguchi","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bmc.2014.11.039","article-title":"Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition","volume":"23","author":"Hamaguchi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib123","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/ml5000993","article-title":"Discovery of novel imidazo[4,5- b ]pyridines as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)","volume":"5","author":"Hu","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113155_bib124","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2011.11.127","article-title":"The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia","volume":"22","author":"Ho","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bmcl.2011.11.023","article-title":"Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia","volume":"22","author":"Yang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib126","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bmcl.2011.12.080","article-title":"Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound","volume":"22","author":"McElroy","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib127","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1016\/j.bmcl.2012.07.072","article-title":"Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia","volume":"22","author":"Raheem","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib128","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.bmcl.2012.01.113","article-title":"The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia","volume":"22","author":"Ho","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib129","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1021\/acs.jmedchem.5b00983","article-title":"Discovery and optimization of a series of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors through fragment screening, structure-based design, and parallel synthesis","volume":"58","author":"Shipe","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib130","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1016\/j.bmc.2013.10.035","article-title":"Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition","volume":"21","author":"Hamaguchi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib131","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.bmc.2014.04.023","article-title":"Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability","volume":"22","author":"Chino","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib132","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bmcl.2015.10.100","article-title":"Fragment-assisted hit investigation involving integrated HTS and fragment screening: application to the identification of phosphodiesterase 10A (PDE10A) inhibitors","volume":"26","author":"Varnes","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib133","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acschemneuro.0c00024","article-title":"Discovery and optimization of chromone derivatives as novel selective phosphodiesterase 10 inhibitors","volume":"11","author":"Yu","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113155_bib134","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1248\/cpb.c17-00836","article-title":"Fragment-based discovery of pyrimido[1,2-B]indazole PDE10A inhibitors, Chem","volume":"66","author":"Chino","year":"2018","journal-title":"Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib135","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1016\/j.bmc.2019.07.010","article-title":"Synthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors","volume":"27","author":"Chino","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib136","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1016\/j.bmcl.2013.10.027","article-title":"Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors","volume":"23","author":"Banerjee","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib137","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1021\/acs.jmedchem.5b01240","article-title":"Design, synthesis, and pharmacological evaluation of 5,6-disubstituted pyridin-2(1H)-one derivatives as phosphodiesterase 10A (PDE10A) antagonists","volume":"58","author":"Lingam","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib138","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.bmcl.2014.03.054","article-title":"Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I, Bioorg","volume":"24","author":"Das","year":"2014","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113155_bib139","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.bmcl.2014.06.028","article-title":"Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part II","volume":"24","author":"Das","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib140","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1021\/jm500073h","article-title":"Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia","volume":"57","author":"Bartolom\u00e9-Nebreda","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib141","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1021\/jm501651a","article-title":"Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia","volume":"58","author":"Bartolom\u00e9-Nebreda","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib142","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1021\/jm5013648","article-title":"Discovery of 1-[2-Fluoro-4-(1 H -pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1 H -pyrazol-5-yl)pyridazin-4(1 H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor","volume":"57","author":"Kunitomo","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib143","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1016\/j.bmc.2016.05.049","article-title":"Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket","volume":"24","author":"Yoshikawa","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib144","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.bmc.2015.10.002","article-title":"Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor","volume":"23","author":"Yoshikawa","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib145","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bmcl.2015.03.050","article-title":"Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A","volume":"25","author":"Burdi","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib146","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.bmc.2017.04.019","article-title":"Design and optimization of purine derivatives as in\u00a0vivo active PDE10A inhibitors","volume":"25","author":"Chen","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib147","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2018.05.043","article-title":"Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines","volume":"155","author":"Moszczy\u0144ski-P\u0119tkowski","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib148","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1248\/cpb.c17-00783","article-title":"Discovery of 2-[(E)-2-(7-fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin- 1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine hydrochloride as a highly selective PDE10A inhibitor","volume":"66","author":"Kadoh","year":"2018","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.113155_bib149","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/j.bmc.2019.06.021","article-title":"Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety","volume":"27","author":"Koizumi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bmcl.2015.11.013","article-title":"Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia","volume":"26","author":"Raheem","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib151","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2018.12.029","article-title":"Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors","volume":"29","author":"Geneste","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib152","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bmcl.2019.03.021","article-title":"Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: hit-to-lead studies","volume":"29","author":"Kawamoto","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib153","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.nucmedbio.2009.12.012","article-title":"Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in\u00a0vitro and in\u00a0vivo evaluation","volume":"37","author":"Tu","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib154","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","article-title":"Radiosynthesis and in\u00a0vivo evaluation of [ 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A","volume":"38","author":"Plisson","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib155","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.bmc.2011.01.032","article-title":"Radiosynthesis and in\u00a0vivo evaluation of [ 11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain","volume":"19","author":"Tu","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib156","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroimage.2013.04.123","article-title":"Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A","volume":"82","author":"Celen","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejmech.2021.113155_bib157","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nucmedbio.2014.09.005","article-title":"Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A","volume":"42","author":"Harada","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib158","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2967\/jnumed.114.140178","article-title":"Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain","volume":"55","author":"Kehler","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib159","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nucmedbio.2014.01.007","article-title":"Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates","volume":"41","author":"Hwang","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib160","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1016\/j.bmcl.2015.05.080","article-title":"Discovery of [11C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors","volume":"25","author":"Cox","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113155_bib161","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11307-015-0910-0","article-title":"Preclinical characterization of the phosphodiesterase 10A PET tracer [11C]MK-8193","volume":"18","author":"Hostetler","year":"2016","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib162","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2967\/jnumed.113.122895","article-title":"In\u00a0vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654","volume":"55","author":"Barret","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib163","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainres.2019.01.021","article-title":"In\u00a0vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [ 18 F]MNI-659","volume":"1711","author":"Svedberg","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.113155_bib164","article-title":"First in\u00a0vivo assessment of two PDE10 tracers [18F]MNI654 and [18F]MNI659","volume":"53","author":"Barret","year":"2012","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib165","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.bmc.2014.03.028","article-title":"Radiosyntheses and in\u00a0vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate","volume":"22","author":"Fan","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neuroimage.2015.07.049","article-title":"Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject","volume":"121","author":"Liu","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejmech.2021.113155_bib167","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2967\/jnumed.113.131409","article-title":"Phosphodiesterase 10a pet radioligand development program: from pig to human","volume":"55","author":"Plisson","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113155_bib168","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/appi.ajp.2015.15040518","article-title":"Phosphodiesterase 10A in schizophrenia: a PET study using [11C]IMA107","volume":"173","author":"Marques","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113155_bib169","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nucmedbio.2015.04.004","article-title":"Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primates","volume":"42","author":"Hwang","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib170","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/acsmedchemlett.6b00185","article-title":"Discovery of phosphodiesterase 10A (PDE10A) PET tracer AMG 580 to support clinical studies","volume":"7","author":"Hu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113155_bib171","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2017.10.004","article-title":"Development of two fluorine-18 labeled PET radioligands targeting PDE10A and in\u00a0vivo PET evaluation in nonhuman primates","volume":"57","author":"Stepanov","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113155_bib172","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/acs.jmedchem.8b01366","article-title":"Development of 2-(2-(3-(4-([ 18 F]fluoromethoxy- d 2 )phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione for positron-emission-tomography imaging of phosphodiesterase 10A in the brain","volume":"62","author":"Mori","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113155_bib173","series-title":"Pyridine and Pyrimidine Derivatives as Phosphodiesterase 10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib174","series-title":"Pyrazine Compounds as Phosphodiesterase 10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib175","series-title":"Aminopyridine and Carboxypyridine Compounds as Phosphodiesterase 10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib176","series-title":"Pde-10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib177","series-title":"Pyridazinone Derivatives","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib178","series-title":"Heteroaryl Substituted Pyridazinone Derivatives","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib179","series-title":"Radiolabelled Pde10 Ligands","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib180","series-title":"Alkoxy Tetrahydro-Pyridopyrimidine Pde10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib181","series-title":"Pyrimidinones as Pde10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib182","series-title":"Substituted Pyrazoloquinolines and Derivatives Thereof","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib183","series-title":"Substituted Triazolopyridines and Analogs Thereof","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib184","series-title":"Radiolabeled Pde10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib185","series-title":"Tri-substituted Pyrimidine Compounds and Their Use as Pde10 Inhibitors","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib186","series-title":"Aromatic Nitrogen-Containing 6-membered Ring Compounds and Their Use","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib187","series-title":"Pde10 Inhibitors and Related Compositions and Methods","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib188","series-title":"Pyridazinone Compounds","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib189","series-title":"Substituted Imidazo[1,5-A]quinoxalines as Inhibitors of Phosphodiesterase 10, Wyeth","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib190","series-title":"Imidazo[5,1-c][1,2,4]benzotriazine Derivatives as Inhibitors of Phosphodiesterases","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib191","series-title":"Triazine Derivatives as Inhibitors of Phosphodiesterases","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113155_bib192","series-title":"Nitrogen Heterocyclic Compounds Useful as Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib193","series-title":"Heteroaryloxycarbocyclyl Compounds as Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib194","series-title":"Heteroaryloxyheterocyclyl Compounds as Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib195","series-title":"Nitrogen- Heterocyclic Compounds as Phosphodiesterase 10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib196","series-title":"Hoffmann-La Roche Ag","author":"Novel imidazopyridines","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib197","series-title":"N-(imidazopyrimidin-7-yl)-heteroarylamide Derivatives and Their Use as Pde10a Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib198","series-title":"Nitrogen-containing Heteroaryl Derivatives","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib199","series-title":"Nitrogen Containing Heteroaryl Compounds","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib200","series-title":"Heteroaryl Compounds as Pde10a Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib201","series-title":"Aryl Substituted Olefinic Compounds as Pde10a Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib202","series-title":"Tricycle Compounds as Phosphodiesterase-10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib203","series-title":"Imidazo[1,2-b]pyridazine Derivatives and Their Use as Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib204","series-title":"Imidazo [1, 2 -a] Pyrazine Derivatives and Their Use for the Prevention or Treatment of Neurological, Psychiatric and Metabolic Disorders and Diseases","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib205","series-title":"Amino Tetrahydro-Pyridopyrimidine Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib206","series-title":"Aryl Aminopyridine Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib207","series-title":"Pyrazolopyrimidine Compounds and Their Use as Pde10 Inhibitors","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib208","series-title":"Pde10 Inhibitors and Related Compositions and Methods","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113155_bib209","series-title":"Substituted 6,7-Dialkoxy-3-Isoquinolinol Derivatives as Inhibitors of Phosphodiesterase 10 (Pde10a)","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib210","series-title":"(1,2,4)triazolo[4,3-a]quinoxaline Derivatives as Inhibitors of Phosphodiesterases","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib211","series-title":"Pyrazolopyridine Compounds as Pde10a Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib212","series-title":"Triazolopyridine Compounds","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib213","series-title":"Imidazole Derivatives as Pde10a Enzyme Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib214","series-title":"Radiolabelled Phenylimidazole-Based Ligands","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib215","series-title":"2-alkoxy Pyrimidine Pde10 Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib216","series-title":"Pyrazolopyrimidine Pde10 Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib217","series-title":"Substituted Amino-Triazolyl Pde10 Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib218","series-title":"Isoindolinone Pde10 Inhibitors","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib219","series-title":"Treatment of Parkinson\u2019s Disease and Enhancement of Dopamine Signal Using PDE 10 Inhibitor","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib220","series-title":"Condensed Heterocyclic Compound","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib221","series-title":"Heterocyclic Compound","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib222","series-title":"Fused Heterocyclic Ring Compound","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib223","series-title":"Heterocyclic Compound and Use Thereof","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib224","series-title":"Fused Heterocyclic Compounds","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113155_bib225","series-title":"Inhibitors of Pde10","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib226","series-title":"Triazolopyridine Compounds as Pde10a Inhibitors","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib227","series-title":"Triazolo Compounds as Pde10 Inhibitors","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib228","series-title":"Pyrrolidino Heterocycles, F. Hoffmann-La Roche Ag","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib229","series-title":"Triazolopyrazine Derivatives and Their Use for Treating Neurological and Psychiatric Disorders","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib230","series-title":"Quinoline Derivatives as Pde10a Enzyme Inhibitors","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib231","series-title":"Imidazole Derivatives as PDE10A Enzyme Inhibitors","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib232","series-title":"Pde10 Modulators","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib233","series-title":"Alkyne-bridged Hetero-Aromatics and Uses Thereof","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib234","series-title":"3-Pyrazolyl-2-pyridone Derivative","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib235","series-title":"Inhibitor Compounds of Phosphodiesterase Type 10A","year":"2014"},{"key":"10.1016\/j.ejmech.2021.113155_bib236","series-title":"Triazolo Compounds","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib237","series-title":"PDE10a Inhibitors for the Treatment of Type II Diabetes","year":"2014"},{"key":"10.1016\/j.ejmech.2021.113155_bib238","series-title":"Aryl- and Heteroaryl- Nitrogen-Heterocyclic Compounds as PDE10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib239","series-title":"Heteroaryloxycarbocyclyl Compounds as PDE10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib240","series-title":"Unsaturated Nitrogen Heterocyclic Compounds Useful as PDE10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib241","series-title":"Fused Triazole Derivatives as Phosphodiesterase 10a Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib242","series-title":"Imidazole Derivatives","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib243","series-title":"(hetero)aryl Imidazoles\/pyrazoles for Treatment of Neurological Disorders","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib244","series-title":"Substituted Imidazo[2,1-A]isoindoles as PDE10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib245","series-title":"2-arylimidazole Derivatives as PDE10A Enzyme Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib246","series-title":"Inhibitors of Phosphodiesterase 10 Enzyme","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib247","series-title":"PDE 10a Inhibitors for the Treatment of Type II Diabetes","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib248","series-title":"Pyrazolopyrimidine PDE 10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib249","series-title":"Aryloxmethyl Cyclopropane Derivatives as PDE10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib250","series-title":"Processes and Intermediates for the Preparation of a Pde10 Inhibitor","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib251","series-title":"Substituted Quinoxalines and Quinoxalinones as PDE-10 Inhibitors","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib252","series-title":"Treatment and Diagnosis of Cancer and Precancerous Conditions Using Pde10a Inhibitors and Methods to Measure Pde10a Expression","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113155_bib253","series-title":"Heteroaryloxyheterocyclyl Compounds as PDE10 Inhibitors","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib254","series-title":"Triazolo Compounds as PDE10 Inhibitors","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib255","series-title":"Substituted Pyridizinone Derivatives as PDE10 Inhibitors","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib256","series-title":"Cyclopropyl Imidazopyridine PDE10 Inhibitors","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib257","series-title":"Secondary Alcohol Substituted Triazoles as PDE10 Inhibitors","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib258","series-title":"Pde10 Inhibitors and Related Compositions and Methods","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib259","series-title":"Pyrimidine Derivatives as Phosphodiesterase 10 Inhibitors (PDE-10)","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113155_bib260","series-title":"Inhibitors of Phosphodiesterase Type 10a","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113155_bib261","series-title":"Heteroaromatic Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113155_bib262","series-title":"Optically Active PDE10 Inhibitor","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113155_bib263","series-title":"Radiolabeled Compounds and Their Use as Radiotracers for Quantitative Imaging of Phosphodiesterase (Pde10a) in Mammals","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113155_bib264","series-title":"Novel Inhibitor Compounds of Phosphodiesterase Type 10a","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113155_bib265","series-title":"Substituted 6, 7-Dialkoxy-3-Isoquinoline Derivatives as Inhibitors of Phosphodiesterase 10 (PDE 10A)","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113155_bib266","series-title":"Substituted [1,2,4]triazolo[1,5-A]pyrazines as Phosphodiesterase Inhibitors","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113155_bib267","series-title":"Inhibitor Compounds of Phosphodiesterase Type 10A","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113155_bib268","series-title":"Methods of Treating Developmental Syndromes with Pde10a Inhibitors","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113155_bib269","series-title":"Pde10a Inhibitors for Treating Negative Symptoms and Cognitive Impairments in a Patient Suffering from Schizophrenia","year":"2020"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:24:51Z","timestamp":1759328691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":269,"alternative-id":["S0223523421000040"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113155","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113155"}}